PolysacDB Capsular polysaccharide 2422

From DrugPedia: A Wikipedia for Drug discovery

Revision as of 06:13, 8 April 2010 by Raghavagps (Talk | contribs)
(diff) ←Older revision | Current revision (diff) | Newer revision→ (diff)
Jump to: navigation, search


Contents

Carbohydrate Name

Capsular polysaccharide

Carbohydrate Class

Capsular polysaccharide

Source Microbe

Streptococcus Group B

Basic Structure

The structure of type III polysaccharide is as follows : -3-β-D-Galp-(1-->4)-β-D-Glcp-(1-->6)-β-D-GlcNAcp-(1--> along with the fact that the carboxyl of the -D-NeuNAcp was linked to the O-3 of the adjacent D-galactose to form the type-specific site


Proposed functions

The property of invasiveness is related to the anti-phagocytic properties conferred to Group B Streptococcus by its capsular polysaccharide

Antigenic Nature used to produce antibodies

Glycoconjugates

Carrier Name

Tetanus toxoid

Conjugation Method

Type III polysaccharide was activated with cyanogen bromide at pH 10.5 for 6 min at 4C. Adipic acid dihydrazide was added in 0.5 M NaHCO3 to a final concentration of 0.25 M, pH 8.5. the reaction mixture was dialyzed against 0.2 M NaCl at 3 to 8C and passed through a 4B-CL Sepharose column. The CP-containing fractions were pooled, dialyzed against sterile pyrogen-free water, and freeze-dried. A solution containing 10 mg each of type III-AH and TT per ml was brought to pH 5.6 with 0.1 N HCl. 1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide was added to a final concentration of 0.05 M. The reaction mixture was dialyzed against 0.2 M NaCl at 3 to 8C and was passed through a 4B-CL Sepharose column

Antibodies

Antisera

Antibody type and class

IgG

Assay System

Double immunodiffusion and capillary precipitation, opsonization assays

Cross-reactivity

This antisera was quite specific and did not react with the structurally related pneumococcus type 14 polysaccharide

Proposed epitopes

N/A

Proposed Utility

Conjugate-induced antibodies facilitated opsonization of group B streptococcus type III organisms. The type III-TT conjugate can be a potential vaccine for prevention of neonatal Group B Streptococcal diseases.

Weblink

PubMed

External Links